ReviewMediators of inflammation2013
Biomarkers in diabetic retinopathy and the therapeutic implications.
Review in Mediators of inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 48 citations in OpenAlex.
- TGF-β Signaling Pathways in the Development of Diabetic Retinopathy.International journal of molecular sciences · 2024Review
- Immune Mediators Profiles in the Aqueous Humor of Patients with Simple Diabetic Retinopathy.Journal of clinical medicine · 2023Article
- Sex-Related Effects of Gut Microbiota in Metabolic Syndrome-Related Diabetic Retinopathy.Microorganisms · 2023Review
- IL-1β Implications in Type 1 Diabetes Mellitus Progression: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- Association of four gene polymorphisms in Chinese Guangxi population with diabetic retinopathy in type 2 diabetic patients.BMC ophthalmology · 2021Article
- Retinal Vascular Endothelial Cell Dysfunction and Neuroretinal Degeneration in Diabetic Patients.Journal of clinical medicine · 2021Review
- ALDH2/SIRT1 Contributes to Type 1 and Type 2 Diabetes-Induced Retinopathy through Depressing Oxidative Stress.Oxidative medicine and cellular longevity · 2021Observational
- Efficacy, Pharmacokinetics, Biodistribution and Excretion of a Novel Acylated Long-Acting Insulin Analogue INS061 in Rats.Drug design, development and therapy · 2021Article
- Inflammatory and angiogenic biomarkers in diabetic retinopathy.Biochemia medica · 2020Review
- Importance of the Use of Oxidative Stress Biomarkers and Inflammatory Profile in Aqueous and Vitreous Humor in Diabetic Retinopathy.Antioxidants (Basel, Switzerland) · 2020Review
- Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes.Journal of clinical medicine · 2020Review
- The Role of Bone Morphogenetic Proteins in Diabetic Complications.ACS pharmacology & translational science · 2020Review
- Relationship between Serum Vascular Endothelial Growth Factor Levels and Stages of Diabetic Retinopathy and Other Biomarkers.Journal of ophthalmology · 2020Article
- Thrombospondin-1: A Key Protein That Induces Fibrosis in Diabetic Complications.Journal of diabetes research · 2020Review
- Vascular endothelial growth factor (VEGF)-related polymorphisms rs10738760 and rs6921438 are not risk factors for proliferative diabetic retinopathy (PDR) in patients with type 2 diabetes mellitus (T2DM).Bosnian journal of basic medical sciences · 2019Article
- Article
- Diabetic Retinopathy and Laser Therapy in Rats: A Protein-Protein Interaction Network Analysis.Journal of lasers in medical sciences · 2017Article
- Marine Organisms with Anti-Diabetes Properties.Marine drugs · 2016Review
- Association between interleukin-19 and angiopoietin-2 with vascular complications in type 2 diabetes.Journal of diabetes investigation · 2016Article
- Unhealthy Phenotype as Indicated by Salivary Biomarkers: Glucose, Insulin, VEGF-A, and IL-12p70 in Obese Kuwaiti Adolescents.Journal of obesity · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main problem both in type 1 (T1DM) and type 2 (T2DM) diabetes is the development of chronic vascular complications encompassing micro- as well as macrocirculation. Chronic complications lower the quality of life, lead to disability, and are the cause of premature death in DM patients. One of the chronic vascular complications is a diabetic retinopathy (DR) which leads to a complete loss of sight in DM patients. Recent trials show that the primary cause of diabetic retinopathy is retinal neovascularization caused by disequilibrium between pro- and antiangiogenic factors. Gaining knowledge of the mechanisms of action of factors influencing retinal neovascularization as well as the search for new, effective treatment methods, especially in advanced stages of DR, puts special importance on research concentrating on the implementation of biological drugs in DR therapy. At present, it is antivascular endothelial growth factor and antitumor necrosis factor that gain particular significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.